A Dose Finding Study of CpG in Patients With Chronic Lymphocytic Leukemia Who Have Been Previously Treated

Completed · Phase 1

Conditions studied: Chronic Lymphocytic Leukemia

In brief

* CpG has the potential to stimulate the immune system * this study will evaluate the safety of CpG given sub-q or IV * purpose is to measure biological changes in CLL cells after receiving CpG

Key facts

Study ID

NCT00233506

Run by

University of Iowa

People needed

41

Starts

2004-07-01

Expected to finish

2011-06-01

Last updated by the study team

2017-02-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of CLL
• CLL previously treated
• Hemoglobin >/= 10
• Platelets >/= 50,000
• Neutrophils >= 1,000 -

You may not qualify if…

• patients with brain mets
• patients with autoimmune disease
• patients on corticosteroids or immunosuppressants
• patients with uncontrolled intercurrent illness
• pregnant women
• HIV patients receiving combination anti-retroviral therapy

Where it is running

• University of Iowa — Iowa City, Iowa, United States
• Mayo Clinic — Rochester, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.